Delaware Supreme Court Affirms Dismissal of Claims Against Benjamin Cravatt

Benjamin Cravatt is free of the litigation that has shadowed his work since Bayer bought Vividion Therapeutics for $2 billion, after the Delaware Supreme Court on Thursday unanimously affirmed the dismissal of every claim against him.

The ruling, handed down en banc in CHP III, L.P. v. Cravatt, No. 70, 2026, shuts down an investor lawsuit that accused the Scripps Research scientist and Vividion co-founder of diverting intellectual property to another of his companies, Belharra Therapeutics, before the 2023 sale. A Keker, Van Nest & Peters team led by R. James Slaughter, Bailey Heaps and Ian Kanig secured the victory.

“Ben Cravatt is an extraordinary scientist whose discoveries have opened new frontiers in medicine and whose companies have created tremendous value,” Slaughter, the firm’s managing partner, said. “He should be spending his time advancing science, not defending himself against lawsuits brought by a disappointed investor.”

Delaware Supreme Court Affirms Dismissal of Claims Against Benjamin Cravatt

The dispute that reached the high court

The case centered on a patent application licensed from Scripps that Vividion relinquished as part of the Bayer transaction. Scripps subsequently licensed that same application to Belharra, another Cravatt-founded venture. The plaintiff, CHP III, L.P., an investment entity controlled by venture capitalist John Clarke, argued that surrendering the IP deprived Vividion shareholders of additional merger consideration and amounted to a direct injury to shareholders.

The Delaware Supreme Court disagreed. It found that CHP failed to allege that relinquishing the intellectual property reduced the $2 billion acquisition price, noting that Bayer had agreed to pay the same amount regardless of which IP rights were released. The Court also rejected CHP’s fraud claim, reinforcing the distinction between direct and derivative shareholder claims under Delaware law.

Partner Laurie Carr Mims and associate Luke Apfeld assisted the Keker team in the Court of Chancery proceedings that preceded the appeal.

Delaware Supreme Court Affirms Dismissal of Claims Against Benjamin Cravatt

A second appellate win in two separate cases

Thursday’s decision marks the second time Keker has defeated Clarke’s litigation against Cravatt at the appellate level. In an earlier suit, Clarke alleged that preliminary discussions about a different biotechnology venture created a binding joint venture. Keker obtained summary judgment for Cravatt and his co-defendants, a ruling the California Court of Appeal affirmed.

Benjamin Cravatt, a professor in the Department of Chemistry at Scripps Research, is considered a co-inventor of activity-based proteomics and a substantial contributor to research on the endocannabinoid system. He was elected to the National Academy of Sciences in 2014 and the American Academy of Arts and Sciences in 2016. In 2026, he was elected to the American Philosophical Society.

Cravatt co-founded Vividion Therapeutics, Abide Therapeutics, ActivX Biosciences, and Belharra Therapeutics. Abide Therapeutics was acquired by Lundbeck Pharmaceuticals, and ActivX Biosciences was acquired by Kyorin Pharmaceuticals. He received the Wolf Prize in Chemistry in 2022.

The Supreme Court’s opinion affirms the dismissal ordered in Delaware Court of Chancery Case No. 2024-0867.